Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature

Archive of Oncology

Volumn 18, Issue 1-2, 2010, Pages 32-35

  Kothari, Rajul ^a   Argenta, Peter ^a   Fowler, Jeffrey ^b   Carter, Jori ^a   Shimp, William ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c Affiliated Community Medical Centers   (United States)

Author keywords

Antineoplastic Agents; Aromatase; Hormonal; Ovarian Neoplasms; Selective Estrogen Receptor Modulators; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FULVESTRANT; GEMCITABINE; PACLITAXEL; TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVARY ADENOCARCINOMA; PAPILLARY CARCINOMA; RECURRENT CANCER; RETROPERITONEAL TUMOR; SALPINGOOOPHORECTOMY; SECOND LOOK SURGERY;

EID: 78649496224     PISSN: 03547310     EISSN: 14509520     Source Type: Journal    
DOI: 10.2298/AOO1002032K     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
2. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69(2):103-8.
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
4. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5(1):26-35.
5. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991;68(2):269-71.
6. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol. 1996;62(1):4-6.
7. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol. 2004;94(2):404-8.
8. Schwartz PE, Chambers JT, Kohorn EI, Chambers SK, Weitzman H, Voynick IM, et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer. 1989;63(6):1074-8.
9. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8(7):2233-9.
10. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2004;66(2):112-7.
11. Argenta PA, Thomas SG, Judson PL, Downs LS, Jr., Geller MA, Carson LF, et al. A phase II study of fulvestrant in the treatment of multiply recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;113(2):205-9.
12. Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley Pillers EM, Wheeler TK, et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer. 1984;50(2):199-205.
13. Goldhirsch A, Joss RA, Leuenberger U, Cavalli F, Ryssel HJ, Brunner KW. An evaluation of tamoxifen dose escalation in advanced breast cancer. Am J Clin Oncol. 1982;5(5):501-3.
14. Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973;1(5844):13-4.
15. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44.
16. Weiner SA, Alberts DS, Surwit EA, Davis J, Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol. 1987;27(2):208-13.
17. Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2001(1):CD001034.
18. Schwartz PE, Keating G, MacLusky N, Naftolin F, Eisenfeld A. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol. 1982;59(5):583-8.
19. Shirey DR, Kavanagh JJ Jr, Gershenson DM, Freedman RS, Copeland LJ, Jones LA. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol. 1985;66(4):575-8.
20. Slevin ML, Harvey VJ, Osborne RJ, Shepherd JH, Williams CJ, Mead GM. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol. 1986;22(3):309-12.
21. Osborne RJ, Malik ST, Slevin ML, Harvey VJ, Spona J, Salzer H et al. Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. Br J Cancer. 1988;57(1):115-6.
22. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol. 1993;11(10):1957-68.
23. Jager W, Sauerbrei W, Beck E, Maassen V, Stumpfe M, Meier W, et al. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res. 1995;15(6B):2639-42.
24. Van der Vange N, Greggi S, Burger CW, Kenemans P, Vermorken JB. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol. 1995;34(6):813-20.
25. Van Der Velden J, Gitsch G, Wain GV, Friedlander ML, Hacker NF. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 1995;5(4):301-5.
26. Marth C, Sorheim N, Kaern, J, Trope C. Tamoxifen in the Treatment of Recurrent Ovarian Carcinoma. Int J Gynecol Cancer. 1997;7:256-61.
27. Markman M, Webster K, Zanotti K, Rohl J, Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol. 2004;93(2):390-3.
28. Karagol H, Saip P, Uygun K, Caloglu M, Eralp Y, Tas F, et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol. 2007;24(1):39-43.
29. Belinson JL, McClure M, Badger G. Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol. 1987;28(2):151-5.
30. Jakobsen A, Bertelsen K, Sell A. Cyclic hormonal treatment in ovarian cancer. A phase- II trial. Eur J Cancer Clin Oncol. 1987;23(7):915-6.
31. Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer. 2005;93(6):647-51.
32. Millward MJ, Cantwell BM, Lien EA, Carmichael J, Harris AL. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer. 1992;28A(4- 5):805-10.
33. Benedetti Panici P, Greggi S, Amoroso M, Scambia G, Battaglia FA, Gebbia V, et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int J Gynecol Cancer. 2001;11(6):438-44.
34. Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol. 2007;105(1):132-7.
35. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007;13(12):3617-22.
36. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, et al. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003;91(3):596-602.